Get the Stockscreener App
1.28
3.23%
0.04
After Hours:
1.25
-0.03
-2.34%
MAIA Biotechnology Inc stock is traded at $1.28, with a volume of 359.25K.
It is up +3.23% in the last 24 hours and down -9.22% over the past month.
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. MAIA Biotechnology, Inc. was incorporated in 2018 and is headquartered in Chicago, Illinois.
See More
Previous Close:
$1.24
Open:
$1.29
24h Volume:
359.25K
Relative Volume:
0.50
Market Cap:
$77.82M
Revenue:
-
Net Income/Loss:
$-24.25M
P/E Ratio:
-1.8835
EPS:
-0.6796
Net Cash Flow:
$-19.95M
1W Performance:
+0.00%
1M Performance:
-9.22%
6M Performance:
-56.61%
1Y Performance:
-24.71%
1-Day Range:
$1.26
$1.315
1-Week Range:
$1.24
$1.35
52-Week Range:
$0.87
$3.19
MAIA Biotechnology Inc Stock (MAIA) Company Profile
Name
MAIA Biotechnology Inc
Sector
Industry
Phone
312 416 8592
Address
444 West Lake Street, Suite 1700, Chicago
Compare MAIA vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MAIA
MAIA Biotechnology Inc
|
1.28 | 75.39M | 0 | -24.25M | -19.95M | -0.6796 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
MAIA Biotechnology Inc Stock (MAIA) Latest News
Maia Biotechnology Inc (MAIA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Maia Biotechnology Inc (MAIA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Maia Biotechnology Inc (MAIA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Maia Biotechnology Inc (MAIA) Institutional Confidence - TradingKey
MAIA|Maia Biotechnology Inc|Price:1.240|Chg%:-0.040 - TradingKey
Maia Biotechnology Inc (MAIA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Maia Biotechnology Inc (MAIA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Maia Biotechnology Inc (MAIA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Maia Biotechnology Inc (MAIA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Maia Biotechnology Inc (MAIA) Valuation: PE, PB & Fair Value Analysis - TradingKey
TradingKey - TradingKey
MAIA Biotechnology Edges Lower as Support Level Faces TestVol Target Rebalance - Bölüm Sonu Canavarı
Noble Financial Sticks to Their Buy Rating for MAIA Biotechnology, Inc. (MAIA) - The Globe and Mail
Data released by MAIA Biotechnology Inc. show that the combination therapy of its candidate drug Apatganosin with Ximiprilizumab demonstrated an acceptable safety profile in a heavily pre-treated population of patients with advanced solid tumors. - Bitget
Maia Biotechnology Reports Initial Efficacy Data from Phase 2 Thio-101 Part C Expansion Trial in Third-Line Non-Small Cell Lung Cancer - marketscreener.com
MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial - The Manila Times
MAIA Biotechnology Reports 90.5% Interim Disease Control Rate in Phase 2 THIO-101 Part C for Advanced NSCLC - Quiver Quantitative
MAIA Biotechnology Reports Strong Initial Efficacy Data in - GlobeNewswire
MAIA Biotechnology (MAIA) Faces Selling Pressure as Shares Approach Key SupportIPO Entry Watch - dars.gov.et
MAIA Biotechnology Inc. (MAIA) Rises 3.1% as Shares Approach Key ResistanceVolume Profile - DonanımHaber
Enterprise value to EBITDA forward of MAIA Biotechnology, Inc. – AMEX:MAIA - TradingView
Price to earnings forward of MAIA Biotechnology, Inc. – BOATS:MAIA - TradingView
MAIAMAIA Biotechnology Inc Dividends - Finviz
ETFs Investing in MAIA Biotechnology, Inc. Stocks - TradingView
MAIA Biotechnology (MAIA) director receives grant of 26,982 stock options - Stock Titan
MAIA Biotechnology (MAIA) director awarded 26,355 stock options at $1.44 - Stock Titan
MAIA Biotechnology (NASDAQ: MAIA) director receives 32,630 stock options grant - Stock Titan
MAIA Biotechnology (NASDAQ: MAIA) director granted 27,610 stock options at $1.44 strike - Stock Titan
Director at MAIA Biotechnology (MAIA) receives 32,003 stock options grant - Stock Titan
26,355 stock options granted to MAIA (NASDAQ: MAIA) director Jean-Manasse - Stock Titan
MAIA Q1 2026 Earnings: Narrower Loss Beats Expectations as Clinical Pipeline AdvancesRevenue Report - dars.gov.et
MAIA Forecast — Price Target — Prediction for 2027 - TradingView
MAIA Biotechnology, Inc. Actuals & Estimates (AMEX:MAIA) - TradingView
MAIA Biotechnology, Inc. Actuals & Estimates (BOATS:MAIA) - TradingView
Why Is MAIA Biotechnology (NYSE:MAIA) Tracking Higher on Trial News? - Kalkine Media
MAIA finishes THIO-101 enrollment abroad, with 41 lung cancer patients treated - Stock Titan
Why Gold Prices Are CrashingACT NOW! Vincenzo Italiano (pm3QIbzhx7) - Fathom Journal
MAIA Biotechnology (MAIA) Edges Higher Amid Biotech Sector Interest — Key Levels in FocusCTA Positioning - dars.gov.et
Noble Financial Maintains MAIA Biotechnology(MAIA.US) With Buy Rating, Maintains Target Price $14 - Moomoo
MAIA Should I Buy - Intellectia AI
MAIA Gains on Setting up New Site - Baystreet.ca
MAIA Biotechnology Opens Enrollment for Phase 2 Expansion - GlobeNewswire
MAIA Biotechnology opens patient enrollment at ... - Pluang
MAIA Biotechnology Surges 4.6%, Approaches Key Resistance at $1.43MESA MA - newsline.com
MAIA Biotechnology Holds Steady at $1.30, Consolidating Between Support and ResistanceETF Creation Redemption - newsline.com
MAIA Biotechnology (MAIA) Holds Steady at $1.30 as Consolidation Phase EmergesStock News - newsline.com
MAIA Biotechnology Q1 2026 Earnings: Narrower Loss and Pipeline Progress Signal Operational DisciplineDividend Increase Stocks - dars.gov.et
MAIA Biotechnology Activates Second US Site for Phase 2 Trial of Lung Cancer Treatment - Moomoo
MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial - The Manila Times
MAIA Biotechnology Activates and Opens Enrollment at Second - GlobeNewswire
MAIA Q1 2026 Earnings: EPS Beat on Lower Net Loss, Focus on Clinical PipelineConsensus Beat Rate - newsline.com
MAIA Biotechnology Inc Stock (MAIA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Cap:
|
Volume (24h):